Ferring Pharmaceuticals successfully launches its third Swiss Franc Bond offering for CHF 330 million

Ferring Pharmaceuticals successfully launches its third Swiss Franc Bond offering for CHF 330 million
27 May 2024 celia

Ad hoc announcement pursuant to Art. 53 LR
Ferring Pharmaceuticals successfully launches its third Swiss Franc Bond offering for CHF 330 million

Saint-Prex, Switzerland – 27 May 2024 – Ferring Pharmaceuticals announced the successful launch of its third Swiss Franc Bond offering for an amount totalling CHF 330 million. This senior unsecured bond transaction issued by Ferring Holding SA comprised two tranches, CHF 210 million with 5-year maturity to 28th June 2029 at a fixed coupon rate of 2.25% per annum, and CHF 120 million with 9-year maturity to 28th June 2033 at a fixed coupon rate of 2.50% per annum. The bonds will be listed on the SIX Swiss Exchange.

The offering attracted interest from high-quality institutional investors and banks, demonstrating continued recognition of the company’s successful track record and solid cash generation from its core business. The company is rated as BBB (UBS) and Baa (Fedafin), both with a stable outlook.

Dominic Moorhead, Chief Financial Officer of Ferring Pharmaceuticals, said: “We are pleased with the successful outcome of our third bond offering and the proceeds will be used for general corporate purposes, as we continue to invest in the launch and development of our new product opportunities.”

The issue was lead-managed by UBS AG and Basler Kantonalbank, with Banque Cantonale Vaudoise acting as co-manager.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X (Twitter).

For more information, please contact

Mary Knight
Global Head, Corporate Values & Communications
+44 7747 758437

Mark Bächer
Media relations, Life Science Communication
+41 78 601 56 08 (mobile)

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.


Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.


Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals


Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.


Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.


Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.